Study guide
6.3 Rh System
Specialist in Blood Banking, SBB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes & Credential Maintenance 1.3 Study Strategy for SBB
2 Donors & Collection
2.1 Donor Qualification 2.2 Collection Methods & Adverse Reactions 2.3 Special Donations
3 Processing, Storage & Component QC
3.1 Processing, Testing & Labeling 3.2 Storage, Transport & Expiration 3.3 Blood Component Quality Control
4 Red Cell & Modified Components
4.1 Whole Blood & Red Blood Cells 4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs 4.3 Irradiated Components 4.4 Granulocytes
5 Platelets, Plasma & Cellular Products
5.1 Platelets 5.2 Plasma & Cryoprecipitated AHF 5.3 Apheresis Products & Fractionation Products 5.4 Hematopoietic Progenitors
6 Genetics, ABO & Rh
6.1 Blood Group Genetics & Molecular Inheritance 6.2 ABO & Lewis Systems 6.3 Rh System 6.4 MNS, P1PK/Globoside & Ii
7 Other Blood Groups & Role in Transfusion
7.1 Kell, Kidd, Duffy & Lutheran 7.2 Other Systems & High/Low-Prevalence Antigens 7.3 HLA, Platelet-Specific & Granulocyte Antigens 7.4 Immunogenicity & Antigen Prevalence
8 Immunology Foundations
8.1 Immune Response 8.2 Immunoglobulins 8.3 Antigen-Antibody Interactions 8.4 Complement
9 Physiology, Hemostasis & HDFN
9.1 Physiology of Blood 9.2 Hemostasis and Coagulation 9.3 HDFN Pathophysiology & Detection 9.4 HDFN Treatment & Prevention
10 Cytopenias & Transplantation
10.1 Immune & Nonimmune Anemia 10.2 Thrombocytopenia & Neutropenia 10.3 Solid Organ Transplantation Support 10.4 Hematopoietic Progenitor Cell Transplantation
11 Routine Serologic Testing
11.1 Blood Grouping Tests 11.2 Antibody Detection & Crossmatch 11.3 Antibody Identification & Clinical Significance 11.4 Direct Antiglobulin Testing & Reagents
12 Special Serologic Methods
12.1 Enzymes, Enhancement Media & Lectins 12.2 Adsorptions, Elutions & Titrations 12.3 Cell Separations, Neutralization & Thiol Reagents 12.4 Chloroquine Diphosphate & EDTA-Glycine Acid
13 Molecular Platforms & Serologic QA
13.1 Molecular Blood Group Techniques 13.2 ELISA, Immunofluorescence, Solid Phase & Column Agglutination 13.3 Serologic Quality Assurance
14 Indications, Component Therapy & PBM
14.1 Indications for Transfusion 14.2 Component Therapy 14.3 Blood Administration & Patient Blood Management
15 Adverse Effects of Transfusion
15.1 Immunologic Transfusion Reactions 15.2 Nonimmunologic Reactions 15.3 Transfusion-Transmitted Diseases
16 Apheresis & Extracorporeal Circulation
16.1 Therapeutic Apheresis 16.2 Extracorporeal Circulation
17 Quality, Safety, Math & Instrumentation
17.1 Quality Assessment & Troubleshooting 17.2 Laboratory Safety 17.3 Laboratory Mathematics 17.4 Instrumentation
18 Laboratory Administration (SBB Only)
18.1 Financial Management 18.2 Operations & Information Technology 18.3 Personnel, Education & Training 18.4 Quality Management, Risk & Tissue Management
6.3 Rh System
Key Takeaways Explain This Topic AI
RHD and RHCE are separate, highly homologous genes on chromosome 1p36.11; unequal recombination between flanking 'Rhesus box' sequences commonly deletes the entire RHD gene, producing the classic Rh-negative phenotype.
Weak D (a quantitative reduction in D antigen density with all epitopes intact) is genetically and clinically distinct from partial D (a qualitative loss of specific D epitopes that can trigger alloimmunization).
Molecularly confirmed weak D types 1, 2, 3, 4.0, and 4.1 can be managed safely as RhD-positive without RhIG or RhD-negative blood, per current AABB/CAP/ACOG/ARC joint guidance.
DVI, the most clinically important partial D, is typically labeled RhD-positive as a donor phenotype but managed as RhD-negative (with RhIG eligibility) as a recipient or obstetric patient, because DVI individuals can form alloanti-D.
Rh-null phenotype arises either from RHAG (regulator-type) or RH-locus (amorph-type) mutations, causes chronic hemolytic anemia with stomatocytosis, and can lead to anti-Rh29, which is incompatible with virtually all red cells except other Rh-null units.
Last updated: July 2026
Rh System
Quick Answer: The Rh system is controlled by two adjacent, highly homologous genes — RHD and RHCE — on chromosome 1p36.11. RHD presence or absence determines D positivity; RHCE determines the C/c and E/e antigens through single amino acid substitutions. The exam-critical distinction is between weak D (quantitatively reduced but complete D antigen) and partial D (qualitatively altered D missing specific epitopes), because the two categories carry opposite transfusion and obstetric management rules.
Two Genes, One Antigen Family
RHD and RHCE lie in tandem on the short arm of chromosome 1, each spanning roughly 75 kb and containing 10 exons, and they are approximately 97% identical in sequence — a homology so high that it drives much of Rh genetic complexity. The C/c polymorphism arises from four linked single-nucleotide changes that together produce one critical amino acid difference (serine versus proline at position 103); the E/e polymorphism arises from a single nucleotide change producing one amino acid difference (alanine versus proline at position 226). D positivity or negativity, in contrast, is usually not a simple point mutation at all: in most Rh-negative individuals of European ancestry, the entire RHD gene is deleted through unequal homologous recombination between two nearly identical 9 kb 'Rhesus box' sequences that flank RHD. In many Rh-negative individuals of African ancestry, RHD is not deleted but is instead present as an inactive pseudogene, RHDψ, silenced by an internal stop codon and a 37-base-pair insertion — a pseudogene that produces no D antigen but that molecular assays must be specifically designed to recognize, or they risk misreporting an inactive RHDψ as an active RHD gene.
Haplotypes and Nomenclature Systems
Because RHD and RHCE are inherited together on the same chromosome far more often than they recombine, specific combinations (haplotypes) occur at characteristic population frequencies. Three parallel naming systems remain in everyday use, and SBB candidates must translate fluently among them:
- Fisher-Race Haplotype Wiener Symbol Antigens Present Approx. Frequency (European-ancestry population)
- DCe R1 D, C, e ~42%
- dce r c, e (no D) ~37%
- DcE R2 D, E, c ~14%
- Dce R0 D, e, c ~4%
- dCe r' C, e (no D) ~2%
- dcE r'' E, c (no D) <1%
- DCE RZ D, C, E Rare
The Rosenfield numeric system (Rh1 = D, Rh2 = C, Rh3 = E, Rh4 = c, Rh5 = e) and the ISBT 004 system provide a third, standardized cross-reference used especially when communicating with reference laboratories and rare-donor registries. Population frequencies differ substantially by ancestry — for example, Rh-negative frequency is roughly 15% in people of European ancestry, roughly 3-8% in people of African ancestry (where the RHDψ pseudogene also complicates simple D-negative counts), and under 1-2% in most Asian populations — a range the SBB exam expects you to apply when reasoning about rare-unit sourcing.
Weak D versus Partial D — the Central SBB Decision
Weak D is a quantitative phenomenon: missense mutations, often in the intracellular or transmembrane portions of the RHD protein, reduce how much D antigen reaches the cell surface, but the full complement of D epitopes is still present, just at lower density. Because every epitope is present, most weak D types are not considered at risk of stimulating alloanti-D production.
Partial D is a qualitative phenomenon: the RHD protein is missing one or more specific epitopes from the normal D mosaic, most often because a segment of RHD sequence has been replaced by the corresponding RHCE sequence through gene conversion. Because specific epitopes are genuinely absent, a partial D individual exposed to normal D-positive red cells can recognize the missing epitopes as foreign and produce a true alloanti-D. DVI is the classic, clinically important partial D: DVI red cells react with most current anti-D reagent blends and are therefore typically labeled RhD-positive as a donor phenotype, yet a DVI recipient or obstetric patient should be managed as RhD-negative — including RhIG eligibility during pregnancy — precisely because that person can form alloanti-D against the D epitopes their own red cells lack.
- Category Antigen Pattern Donor Labeling Recipient / OB Management
- Weak D types 1, 2, 3, 4.0, 4.1 Reduced density, full epitope set RhD-positive RhD-positive; no RhIG needed
- Partial D (e.g., DVI) Missing specific epitopes Usually RhD-positive RhD-negative; RhIG-eligible
Serologic weak D, molecular type unresolved Unknown Refer for RHD genotyping Manage as RhD-negative until resolved
All other rare/uncharacterized weak D types Variable, unconfirmed risk Case-by-case, typically RhD-positive RhD-negative, out of caution
Current joint guidance from AABB, CAP, ACOG, America's Blood Centers, and the American Red Cross recommends resolving every serologic weak D result in a transfusion recipient or a woman of childbearing potential with RHD genotyping rather than relying on serology alone. Individuals confirmed as weak D type 1, 2, 3, 4.0, or 4.1 can be managed safely as RhD-positive — they do not need RhIG and do not need to be reserved RhD-negative units — because high-quality evidence shows they are not meaningfully at risk of forming alloanti-D. All other, rarer, or as-yet-uncharacterized weak D types are managed conservatively as RhD-negative until further evidence justifies otherwise. This workflow (initial weak agglutination at the antihuman-globulin phase, referral for genotyping, then classification and rule application) is exactly the kind of multi-step decision the SBB exam tests candidates on, because it requires combining serologic recognition with genetics-based risk stratification.
Rh-null and Rh-mod Phenotypes
Inserting Rh polypeptides into the red cell membrane requires a partner protein, RhAG, encoded by RHAG on chromosome 6. Two distinct genetic mechanisms can eliminate Rh antigen expression entirely, producing the rare Rh-null phenotype:
Regulator type — Mutations in RHAG itself silence Rh antigen expression even though the person's own RHD and RHCE genes are structurally normal, because without functional RhAG, the Rh polypeptides cannot be transported to the membrane.
Amorph type — Mutations directly at the RH locus (RHD and RHCE themselves) eliminate Rh antigen production without any RHAG defect.
Because the RhAG-Rh complex also has a structural role in the membrane, Rh-null red cells commonly display stomatocytosis and a chronic, usually well-compensated hemolytic anemia. Rh-null individuals who become alloimmunized can develop anti-Rh29 , an antibody directed against the entire Rh protein complex rather than a single antigen, which makes essentially all Rh-positive and ordinary Rh-negative red cells incompatible — these patients depend on rare-donor registries or autologous blood for transfusion support. A milder, partial version of RhAG deficiency produces the Rh-mod phenotype, with weak but detectable Rh antigen expression and a correspondingly milder clinical picture.